Navigation Links
QuantaLife, Inc. Closes $17.2M Series B Financing to Accelerate Application Development for Its Droplet Digital™ PCR Platform and Establish Commercial Operations by 2011
Date:12/10/2010

PLEASANTON, Calif., Dec. 10, 2010 /PRNewswire/ --

QuantaLife, Inc. announced today that it has closed a $17.2M Series B financing. The majority of the proceeds will be used to establish commercial operations for introduction of its first product, the Droplet Digital™ PCR platform, into the life sciences research market early next year and accelerate development of targeted diagnostic tests. Paladin Capital Group, together with other existing investors reiterated their strong support and was joined by Merieux Developpement and Vital Financial LLC, as new investors. According to Dr. Bill Colston, Founder and Chief Executive Officer of QuantaLife, "Droplet Digital PCR establishes a new standard for nucleic acid measurement, including the absolute quantification of DNA, RNA, and miRNA. It has a myriad of potential uses – in the research laboratory and in the clinic. With the completion of this financing, we have diversified our world-class investor base and are well positioned for a successful transition to commercialization.   We look forward to bringing a cost-effective and reliable product to the research community."

"QuantaLife's technology is very compelling and represents a unique opportunity to establish a new standard for the future of genomics research and nucleic acid testing, with a simple, reliable and cost-effective solution. We look forward to working with QuantaLife's management team and existing shareholders to help establish the company as a global leader in the emerging digital PCR market," said Francois Valencony, Managing Director of Merieux Developpement.

About QuantaLife, Inc.

QuantaLife has developed 3rd generation PCR technology that quantifies DNA molecules by Droplet Digital PCR. Droplet Digital PCR measures target nucleic acid target molecules with unrivaled absolut
'/>"/>

SOURCE QuantaLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. QuantaLife, Inc. Unanimously Selected as the Most Promising Company at the Personalized Medicine World Conference 2010
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
4. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
5. Calithera Biosciences Closes $40 Million in Series A Financing
6. Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
7. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
8. YM BioSciences closes US$17.5 million financing
9. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
10. Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round
11. The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014 /PRNewswire/ ... will be a 177-key, 4-star boutique hotel in the heart ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... the first hotel within ATLAS , The ... mixture of standard rooms and suites, a sleek restaurant and bar, ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... -- Research and Markets  has announced the ... report to their offering. ... Metabonomics is the scientific study of chemical processes ... technique that is being widely used in biology, ... molecules that are present in blood, urine, and ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... with live study setup and launch..., WAYLAND, ... in bio-pharmaceutical clinical trials software, announces the,launch of ... studies. Trident,s unique parameter driven + custom pluggable ... to deliver a new era,of needed scalability, productivity, ...
... March 20 NexGen,Biofuels Ltd. (OTC:NXGNF) announced today ... shares have been approved for quotation on the,OTC-Bulletin ... a development stage company that is currently seeking ... blending assets in,the United States., For More ...
... Therapies Will Not Match, the Current Gold-Standard ... According to a New Report ... Decision Resources, one of the,world,s leading research and advisory ... drug Zactima from AstraZeneca,will earn 4.7 percent patient share ...
Cached Biology Technology:Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016 2
(Date:7/28/2014)... A study of juvenile rat brain cells suggests that ... the connections between brain cells are temporary. , The ... PLOS ONE , was conducted by biologists at ... Medical College in New York in response to concerns, ... decade, that exposing children to general anesthetics may increase ...
(Date:7/28/2014)... areas of the Earth that are high priorities for ... is particularly vulnerable, as it has the lowest fraction ... any continent in ,refugia, areas of biological diversity ... relatively constant during times of great environmental change. The ... Scandinavia and Scotland. , The biggest refugia are ...
(Date:7/28/2014)... tool that can help advance the genetic engineering ... bioenergy, has been developed by researchers with the ... (JBEI), a multi-institutional partnership led by Lawrence Berkeley ... developed an assay that enables scientists to identify ... critical components in the biosynthesis of plant cell ...
Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3
... clinical research is being done, warns a senior doctor ... is failing patients and clinicians by neglecting this vital ... information that doctors need to diagnose and treat patients ... field of neurology alone, many examples exist where a ...
... and Geoff Garnett (of Imperial College London) suggests that ... controlled through antiretroviral drugs alone, even if universal access ... the open-access international medical journal PLoS Medicine, without additional ... about safe sex, access to drugs is likely to ...
... causes mice to develop the metabolic syndrome, researchers at ... at OHSU, the University of Texas Medical Branch and ... lack the gene encoding the DNA repair enzyme NEIL1 ... twice the weight of their normal counterparts. The mice, ...
Cached Biology News:Access to antiretrovirals unlikely to reduce HIV infection rates 2Removing DNA repair gene causes metabolic syndrome 2Removing DNA repair gene causes metabolic syndrome 3
... Systems provide fast and reliable automation ... and drug development laboratories. Staccato Custom ... specifications, providing solutions that are tailored ... Custom Systems are controlled with either ...
... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• Is ... large molecules, such as antibodies, that ... interact with the surface,• Binding capacity ...
... tabs • Reusable, press-to-seal gasket and ... assembled and disassembled for hybridizing and imaging ... thickness with up to a 13 mm ... slide. Minimize specimen handling, eliminate evaporation and ...
...
Biology Products: